Insulet PODD Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's total cost of revenue?
- Insulet (PODD) reported total cost of revenue of $232.7M in Q1 2026.
- How has Insulet's total cost of revenue changed year-over-year?
- Insulet's total cost of revenue increased by 45.5% year-over-year, from $159.9M to $232.7M.
- What is the long-term trend for Insulet's total cost of revenue?
- Over 4 years (2021 to 2025), Insulet's total cost of revenue has grown at a 22.0% compound annual growth rate (CAGR), from $346.7M to $768.2M.
- What does total cost of revenue mean?
- The direct costs incurred to produce the goods or services sold by the company.
- How do you interpret total cost of revenue?
- A decrease relative to revenue suggests improved manufacturing efficiency or economies of scale, while an increase may indicate rising input costs.
- How does total cost of revenue compare across companies?
- Varies by industry; medical device manufacturers often have higher costs due to regulatory and quality control requirements.